1. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—Executive summary.;Hering;Xenotransplantation,2016
2. Food and Drug Administration. Source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans; guidance for industry. 2016 [cited 2024 May 24]. https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/xenotransplantation/ucm533036.pdf
3. Food and Drug Administration. PHS guideline on infectious disease issues in xenotransplantation. 66 F.R. 8120. 2001 [cited 2024 May 24]. https://www.federalregister.gov/documents/2001/01/29/01-2419/phs-guideline-on-infectious-disease-issues-in-xenotransplantation-availability
4. World Health Organization. Second WHO global consultation on regulatory requirements for xenotransplantation clinical trials. 2001 [cited 2024 May 24]. https://www.who.int/transplantation/xeno/report2nd_global_consultation_xtx.pdf
5. Third WHO global consultation on regulatory requirements for xenotransplantation clinical trials, Changsha, Hunan, China, December 12–14, 2018.;Hawthorne;Xenotransplantation,2019